Working… Menu

Clinical Trial of BI 425809 Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-3)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04860830
Recruitment Status : Recruiting
First Posted : April 27, 2021
Last Update Posted : July 28, 2021
Information provided by (Responsible Party):
Boehringer Ingelheim

Brief Summary:

This study is open to adults with schizophrenia. Schizophrenia can affect the way a person thinks, their memory and their mental functioning. Examples include struggling to remember things, or to read a book or pay attention to a movie. Some people have difficulty calculating the right change or planning a trip so that they arrive on time. The purpose of this study is to find out whether a medicine called BI 425809 improves learning and memory in people with schizophrenia.

Participants are put into two groups randomly, which means by chance. One group takes BI 425809 tablets and the other group takes placebo tablets. Placebo tablets look like BI 425809 tablets but do not contain any medicine. Participants take a tablet once a day for 26 weeks. In addition, all participants take their normal medication for schizophrenia.

During this time, doctors regularly test learning and memory of the participants by use of questionnaires, interviews, and computer tests. The results of the mental ability tests are compared between the groups.

Participants are in the study for about 8 months and visit the study site about 14 times. During this time, doctors regularly check participants' health and take note of any unwanted effects.

Condition or disease Intervention/treatment Phase
Schizophrenia Drug: BI 425809 Drug: Placebo Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 586 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase III Randomized, Double-blind, Placebo-controlled Parallel Group Trial to Examine the Efficacy and Safety of BI 425809 Once Daily Over 26 Week Treatment Period in Patients With Schizophrenia (CONNEX-3)
Actual Study Start Date : June 18, 2021
Estimated Primary Completion Date : April 5, 2024
Estimated Study Completion Date : May 3, 2024

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Schizophrenia

Arm Intervention/treatment
Experimental: BI 425809 treatment group Drug: BI 425809
BI 425809

Placebo Comparator: Placebo group Drug: Placebo

Primary Outcome Measures :
  1. Change from baseline in overall composite T-score of the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) consensus cognitive battery (MCCB) [ Time Frame: After 26 weeks of treatment ]
    MCCB comprises 10 tests, which assess 7 cognitive domains, including speed of processing, attention vigilance, working memory, verbal learning, visual learning, reasoning and problem solving, and social cognition

Secondary Outcome Measures :
  1. Change from baseline in the Schizophrenia Cognition Rating Scale (SCoRS) interviewer total score [ Time Frame: After 26 weeks of treatment ]
    SCoRS is a 20-item interview-based assessment of cognitive deficits and the degree to which they affect day-to-day functioning. Each item is rated on a 4-point scale. Higher ratings reflect a greater degree of impairment.

  2. Change from baseline to Week 26 in the adjusted total time in the Virtual Reality Functional Capacity Assessment Tool (VRFCAT) [ Time Frame: Up to week 26 ]
  3. Change from baseline to Week 26 in the T-score of the number of correct responses on Tower of London [ Time Frame: Up to week 26 ]
  4. Change from screening visit 1a to Week 24 in Patient Reported Experience of Cognitive Impairment in Schizophrenia (PRECIS) total score [ Time Frame: Up to week 24 ]
    PRECIS is a patient reported outcome (PRO) for recording patients' subjective experience of Cognitive Impairment Associated with Schizophrenia (CIAS). The questionnaire contains 28 items covering 6 domains: Memory (6 items), communication (4 items), self-control (3 items), executive function (4 items), attention (6 items), and sharp thinking (3 items). Two additional items assess the overall degree of bother associated with all domains. Questions are answered via a 5-category Likert scale, with higher scores corresponding to worse patient experience. The Total Score is derived by calculating the simple average score of the first 26 items.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria

  • Signed and dated written informed consent.
  • Male or female patients who are 18-50 years (inclusive) of age at time of consent.
  • Diagnosis of schizophrenia utilizing Diagnostic and Statistical Manual of Mental Disorders 5th Edition (DSM-5).

    -- Patients must be clinically stable and in the residual (non-acute) phase of their illness with no hospitalization or increase level of care due to worsening of schizophrenia in the past 12 weeks or no uncontrolled positive symptoms.

  • Patients should have functional impairment in day-to-day activities per investigator judgement.
  • Patients maintained on current antipsychotic treatment for at least 12 weeks and on current dose for at least 35 days prior to randomization.
  • Patients with any other concomitant psychoactive medications (except for anticholinergics) need to be maintained on same drug for at least 12 weeks and on current dose/ regimen for at least 35 days prior to randomization.
  • Women of childbearing potential must use highly effective methods of birth control.
  • Have a study partner who interacts with the patient on a regular basis. Further inclusion criteria apply.

Exclusion criteria

  • Patient with current DSM-5 diagnosis other than Schizophrenia.
  • Cognitive impairment due to other causes, or patients with dementia.
  • Severe movement disorders.
  • Any suicidal behavior in past year or suicidal ideation in the past 3 months.
  • History of moderate or severe substance use disorder within the last 12 months prior to informed consent.
  • Positive urine drug screen.
  • Patients who were treated with Clozapine, stimulants, ketamine or electroconvulsive therapy within 6 months prior to randomization.
  • Current participation in any investigational drug trial.
  • Cognitive Remediation Therapy within 12 weeks prior to screening.
  • Initiation or change in any type or frequency of psychotherapy within 12 weeks prior to randomization.
  • Any clinically significant finding or condition that would jeopardize the patient´s safety while participating in the trial or their capability to participate in the trial.
  • Haemoglobin (Hb) below lower limit of normal .
  • History of haemolytic anaemia, red blood cell (RBC) membrane diseases, known Glucose-6-phosphate dehydrogenase deficiency, anaemia of any cause or patients planning to donate blood.
  • Severe renal impairment.
  • Indication of liver disease.
  • Any documented active or suspected malignancy or history of malignancy within 5 years.
  • Women who are pregnant, nursing, or who plan to become pregnant while in the trial.

Further exclusion criteria apply.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04860830

Layout table for location contacts
Contact: Boehringer Ingelheim 1-800-243-0127

Layout table for location information
United States, California
Behavioral Research Specialists, LLC Recruiting
Glendale, California, United States, 91206
Contact: Jesse Carr    +001 (888) 255-5798   
Beijing Anding Hospital Recruiting
Beijing, China, 100088
Contact: Gang Wang    13661106500   
INEP medical s.r.o. Recruiting
Prague, Czechia, 18600
Contact: Alexander Nawka    +420 222 201 020   
Aarhus University Hospital Recruiting
Aarhus, Denmark, 8200
Contact: Ole Mors    +45 29479780   
Psykiatrisk Center Glostrup Recruiting
Glostrup, Denmark, 2600
Contact: Bjørn Ebdrup    +45 26133832   
Studienzentrum für Neurologie und Psychiatrie Recruiting
Böblingen, Germany, 71034
Contact: Felix Bischof    +49 151-070389535   
Klinikum der Universität München - Campus Innenstadt Recruiting
München, Germany, 80336
Contact: Peter Falkai    +49 (89) 4400-55501   
Korea, Republic of
Inje University Busan Paik Hospital Recruiting
Busan, Korea, Republic of, 47392
Contact: Do-Un Jung    82 51 890 6189   
Chonnam National University Hospital Recruiting
Gwangju, Korea, Republic of, 61453
Contact: Sung-Wan Kim    82 62 220 6148   
CHA Bundang Medical Center Recruiting
Seongnam, Korea, Republic of, 13496
Contact: Sang-Hyuk Lee    82 31 780 5865   
Seoul National University Bundang Hospital Recruiting
Seongnam, Korea, Republic of, 13620
Contact: Euitae Kim    82 31 787 7435   
Pusan National University Yangsan Hospital Recruiting
Yangsan, Korea, Republic of, 50612
Contact: Tae Young Lee    82 55 360 2468   
Sponsors and Collaborators
Boehringer Ingelheim
Additional Information:
Layout table for additonal information
Responsible Party: Boehringer Ingelheim Identifier: NCT04860830    
Other Study ID Numbers: 1346-0013
First Posted: April 27, 2021    Key Record Dates
Last Update Posted: July 28, 2021
Last Verified: July 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description:

After the study is completed and the primary manuscript is accepted for publishing, researchers can use this following link to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement".

Also, Researchers can use the following link to find information in order to request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.

The data shared are the raw clinical study data sets.

Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Clinical Study Report (CSR)
Time Frame: After all regulatory activities are completed in the US and EU for the product and indication, and after the primary manuscript has been accepted for publication.
Access Criteria: For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by both the independent review panel and the sponsor, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a 'Data Sharing Agreement'.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders